For research use only. Not for therapeutic Use.
HMN-176(CAT: I002260) is a stilbene derivative known for its unique mechanism of action. This compound exerts its pharmacological effects by inhibiting mitosis, the process of cell division, without significantly affecting tubulin polymerization, which is essential for forming the microtubule structures involved in cell division. By specifically targeting mitosis, HMN-176 holds promise as a potential anticancer agent, disrupting the critical cellular process necessary for the proliferation of cancer cells.
| Catalog Number | I002260 |
| CAS Number | 173529-10-7 |
| Molecular Formula | C20H18N2O4S |
| Purity | ≥95% |
| Target | Polo-like Kinase (PLK) |
| Solubility | DMSO: ≥ 30 mg/mL |
| Storage | -20°C |
| Reference | </br>1:The small organic compound HMN-176 delays satisfaction of the spindle assembly checkpoint by inhibiting centrosome-dependent microtubule nucleation. DiMaio MA, Mikhailov A, Rieder CL, Von Hoff DD, Palazzo RE.Mol Cancer Ther. 2009 Mar;8(3):592-601. doi: 10.1158/1535-7163.MCT-08-0876. Epub 2009 Mar 3. PMID: 19258425 Free PMC Article</br>2:Investigation of HMN-176 anticancer activity in human tumor specimens in vitro and the effects of HMN-176 on differential gene expression. Medina-Gundrum L, Cerna C, Gomez L, Izbicka E.Invest New Drugs. 2005 Jan;23(1):3-9. PMID: 15528975 </br>3:In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176. Takagi M, Honmura T, Watanabe S, Yamaguchi R, Nogawa M, Nishimura I, Katoh F, Matsuda M, Hidaka H.Invest New Drugs. 2003 Nov;21(4):387-99. PMID: 14586206 </br>4:HMN-176, an active metabolite of the synthetic antitumor agent HMN-214, restores chemosensitivity to multidrug-resistant cells by targeting the transcription factor NF-Y. Tanaka H, Ohshima N, Ikenoya M, Komori K, Katoh F, Hidaka H.Cancer Res. 2003 Oct 15;63(20):6942-7. PMID: 14583495 Free Article |
